The significantly improved overall survival and patient-reported measures in CARTITUDE-4 reinforce the use of cilta-cel in treating relapsed or refractory multiple myeloma as early as after first relapse.
[Articles] Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
The Lancet Oncology | | Hermann Einsele, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels WCJ van de Donk, Surbhi Sidana, Albert Oriol, Yael C Cohen, Simon J Harrison, María-Victoria Mateos, Joaquín Martínez-López, Paolo Corradini, Lionel Karlin, Diana Chen, Quanlin Li, Tzu-min Yeh, Katherine Li, Vicki Plaks, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Jordan M Schecter, Nikoletta Lendvai, Mythili Koneru, Nitin Patel, Erika Florendo, Phoebe Joy Ho, Rakesh Popat
Topics: blood-cancer, clinical-trials